Physician profile
Robert K Ullom
NPI 1902034614
$2,773.13
in general payments reported to CMS, 2019-2025
33 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $256 · 2021: $679 · 2022: $481 · 2023: $224 · 2024: $251 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.11 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $243.80 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $221.64 | 2019-2023 | Ubrelvy |
| Novo Nordisk INC | $220.35 | 2019-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $210.79 | 2021 | |
| Lilly USA, LLC | $144.85 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $127.29 | 2019-2021 | |
| Allergan, INC. | $124.80 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.52 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $122.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $86.83 | 2021-2022 | |
| Amarin Pharma, INC. | $85.89 | 2020-2022 | |
| Eisai INC. | $77.69 | 2020-2022 | |
| Medtronic, INC. | $65.48 | 2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.54 | 2021-2023 | Xifaxan, Trulance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.29 | 2021-2022 | |
| Pfizer INC. | $52.65 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $44.02 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $41.61 | 2023-2025 | Gemtesa |
| Nevro Corp. | $34.38 | 2023 | Senza |
| Dexcom, INC. | $28.74 | 2024 | Dexcom G7 Gss (161) |
| Grifols USA, LLC | $24.74 | 2025 | Prolastin-C Liquid |
| Sanofi Pasteur INC. | $22.38 | 2025 | |
| Cranial Technologies, INC | $20.61 | 2024 | Doc Band |
| Inspire Medical Systems, INC. | $14.97 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $13.08 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2022 | |
| Neos Therapeutics, LP | $13.01 | 2022 | |
| Daiichi Sankyo INC. | $12.52 | 2021 | |
| Merck Sharp & Dohme LLC | $12.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.15 | 2021 | |
| Esperion Therapeutics, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ullom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.